Chinese Journal of Antituberculosis ›› 2019, Vol. 41 ›› Issue (5): 564-568.doi: 10.3969/j.issn.1000-6621.2019.05.017
• Original Articles • Previous Articles Next Articles
Xi LONG1,*,Mei LIN2(),Ru-shu LAN2,Zhe-zhe CUI2,Da-bin LIANG2,Ding-wen LIN2,Dan LUO3,Jing YE2,Hui-fang QIN2,Li-wen HUANG,Min-ying HUANG
Received:
2018-11-30
Online:
2019-05-10
Published:
2019-05-10
Contact:
Xi LONG
E-mail:gxlinmei@126.com
Xi LONG,Mei LIN,Ru-shu LAN,Zhe-zhe CUI,Da-bin LIANG,Ding-wen LIN,Dan LUO,Jing YE,Hui-fang QIN,Li-wen HUANG,Min-ying HUANG. Epidemic and influencing factors of drug-resistant tuberculosis in border and non-border area of Guangxi[J]. Chinese Journal of Antituberculosis, 2019, 41(5): 564-568. doi: 10.3969/j.issn.1000-6621.2019.05.017
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2019.05.017
药敏试验 结果 | 合计(1306株) | 边境组(631株) | 非边境组(675株) | χ2值 | P值 | |||
---|---|---|---|---|---|---|---|---|
菌株数 | 耐药率(%) | 菌株数 | 耐药率(%) | 菌株数 | 耐药率(%) | |||
任一耐H | 111 | 8.5 | 68 | 10.8 | 43 | 6.4 | 8.14 | 0.004 |
任一耐R | 65 | 5.0 | 53 | 8.4 | 12 | 1.8 | 30.24 | <0.001 |
任一耐E | 32 | 2.5 | 16 | 2.5 | 16 | 2.4 | 0.04 | 0.847 |
任一耐S | 72 | 5.5 | 41 | 6.5 | 31 | 4.6 | 2.27 | 0.132 |
任一耐Km | 6 | 0.5 | 4 | 0.6 | 2 | 0.3 | 0.24 | 0.623 |
任一耐Ofx | 36 | 2.8 | 22 | 3.5 | 14 | 2.1 | 2.43 | 0.119 |
影响因素 | 边境组 | 非边境组 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
例数 | 耐药 例数 | 耐药率 (%) | χ2值 | P值 | 例数 | 耐药 例数 | 耐药率 (%) | χ2值 | P值 | |
性别 | 1.12 | 0.290 | 0.01 | 0.922 | ||||||
女 | 122 | 18 | 14.8 | 150 | 17 | 11.3 | ||||
男 | 509 | 96 | 18.9 | 525 | 58 | 11.0 | ||||
年龄组(岁) | 0.95 | 0.623 | 2.38 | 0.304 | ||||||
0~ | 87 | 13 | 14.9 | 112 | 12 | 10.7 | ||||
31~ | 365 | 70 | 19.2 | 334 | 43 | 12.9 | ||||
61~ | 179 | 31 | 17.3 | 229 | 20 | 8.7 | ||||
现住址 | 0.13 | 0.720 | 0.01 | 0.918 | ||||||
城镇 | 109 | 21 | 19.3 | 132 | 15 | 11.4 | ||||
农村 | 522 | 93 | 17.8 | 543 | 60 | 11.1 | ||||
民族 | 0.55 | 0.759 | 1.42 | 0.491 | ||||||
汉族 | 118 | 19 | 16.1 | 603 | 64 | 10.6 | ||||
壮族 | 493 | 92 | 18.7 | 53 | 8 | 15.1 | ||||
其他a | 20 | 3 | 15.0 | 19 | 3 | 15.8 | ||||
职业 | 0.01 | 0.932 | 0.14 | 0.710 | ||||||
农民 | 500 | 90 | 18.0 | 538 | 61 | 11.3 | ||||
其他b | 131 | 24 | 18.3 | 137 | 14 | 10.2 | ||||
家庭年收入(元) | 3.35 | 0.067 | 0.17 | 0.685 | ||||||
≤20000 | 278 | 59 | 21.2 | 221 | 23 | 10.4 | ||||
>20000 | 353 | 55 | 15.6 | 454 | 52 | 11.5 | ||||
文化水平 | 2.22 | 0.137 | 0.69 | 0.408 | ||||||
初中以下 | 276 | 57 | 20.7 | 282 | 28 | 9.9 | ||||
初中及以上 | 355 | 57 | 16.1 | 393 | 47 | 12.0 | ||||
患者类型 | 6.10 | 0.014 | 9.06 | 0.003 | ||||||
初治 | 530 | 87 | 16.4 | 619 | 62 | 10.0 | ||||
复治 | 101 | 27 | 26.7 | 56 | 13 | 23.2 | ||||
累及肺野数(个) | 2.52 | 0.112 | 2.29 | 0.130 | ||||||
≤3 | 297 | 46 | 15.5 | 289 | 26 | 9.0 | ||||
>3 | 334 | 68 | 20.4 | 386 | 49 | 12.7 | ||||
有无空洞 | 1.90 | 0.168 | 0.67 | 0.414 | ||||||
无 | 252 | 39 | 15.5 | 250 | 31 | 12.4 | ||||
有 | 379 | 75 | 19.8 | 425 | 44 | 10.4 |
[1] | 黄曙海, 蓝如束, 刘飞鹰 , 等. 广西壮族自治区肺结核耐药性调查及复治患者耐药相关因素分析. 中国防痨杂志, 2013,35(9):711-717. |
[2] | 赵雁林, 逄宇 . 结核病实验室检验规程.北京: 人民卫生出版社, 2015: 45-53. |
[3] |
刘二勇, 周林, 王黎霞 . 《WS 196—2017结核病分类》标准全面解读. 中国防痨杂志, 2018,40(3):234-238.
doi: 10.3969/j.issn.1000-6621.2018.03.003 URL |
[4] | World Health Organization . Global tuberculosis report 2018. Geneva:World Health Organization, 2018. |
[5] | 白大鹏, 孔伟利, 张丽霞 . 2006-2017年天津市结核分枝杆菌耐药性分析. 中华医院感染学杂志, 2019,29(3):346-350. |
[6] |
Nhung NV, Hoa NB, Sy DN , et al. The fourth national anti-tuberculosis drug resistance survey in Viet Nam. Int J Tuberc Lung Dis, 2015,19(6):670-675.
doi: 10.5588/ijtld.14.0785 URL pmid: 25946357 |
[7] |
巫株华, 黎贞燕, 李宇轩 , 等. 广东省2911例涂阳肺结核病患者的耐药疫情分析. 广东医学, 2018,39(2):228-234.
doi: 10.3969/j.issn.1001-9448.2018.02.016 URL |
[8] |
沈欣, 雷世光, 宋沈超 , 等. 2015年贵州省肺结核患者耐药监测情况分析. 临床肺科杂志, 2017,22(5):781-784.
doi: 10.3969/j.issn.1009-6663.2017.05.002 URL |
[9] | 杨星, 陈连勇, 马利 , 等. 2012-2014年云南省结核分枝杆菌耐药分析. 现代预防医学, 2016,43(12):2263-2266,2279. |
[10] |
刘彬彬, 胡培磊, 龚道方 , 等. 湖南省涂阳肺结核患者结核分枝杆菌耐药谱及其影响因素. 中国感染控制杂志, 2016,15(2):73-78.
doi: 10.3969/j.issn.1671-9638.2016.02.001 URL |
[11] |
高会霞, 侯军良, 张志 , 等. 346例肺结核患者结核分枝杆菌耐药性调查及耐多药结核病影响因素分析. 中国防痨杂志, 2015,37(11):1130-1135.
doi: 10.3969/j.issn.1000-6621.2015.11.010 URL |
[12] |
刘彬彬, 胡培磊, 龚道方 , 等. 湖南省涂阳肺结核患者结核分枝杆菌耐药谱及其影响因素. 中国感染控制杂志, 2016,15(2):73-78.
doi: 10.3969/j.issn.1671-9638.2016.02.001 URL |
[13] | Yang C, Luo T, Shen X , et al. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis, 2017,17(3):275-284. |
[14] | Ullah I, Javaid A, Tahir Z , et al. Pattern of Drug Resistance and Risk Factors Associated with Development of Drug Resis-tant Mycobacterium tuberculosis in Pakistan. PLoS One, 2016,11(1):e0147529. |
[15] |
Zhang C, Wang Y, Shi G , et al. Determinants of multidrug-resistant tuberculosis in Henan province in China: a case control study. BMC Public Health, 2016,16:42.
doi: 10.1186/s12889-016-2711-z URL pmid: 4715352 |
[16] |
梁立波, 李玲, 孙宏 , 等. 耐多药结核流行及影响因素研究进展. 中国公共卫生, 2014,30(9):1221-1225.
doi: 10.11847/zgggws2014-30-09-37 URL |
[17] |
张国钦, 钟达 . 耐药肺结核发生和流行的危险因素. 中国慢性病预防与控制, 2017,25(7):557-560.
doi: 10.16386/j.cjpccd.issn.1004-6194.2017.07.023 URL |
[18] |
Alene KA, Yi H, Viney K , et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect Dis, 2017,17(1):573.
doi: 10.1186/s12879-017-2662-8 URL pmid: 28814276 |
[19] | Zumla A, George A, Sharma V , et al. The WHO 2014 global tuberculosis report-further to go. The Lancet Global Health, 2015,3(1):e10-e12. |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||